SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is currently trending as investors monitor ivonescimab's potential to disrupt the oncology market, with heavy focus on its head-to-head performance against Keytruda. The community is actively debating the company's future ahead of upcoming clinical data, balancing optimism about its transformative pipeline against concerns regarding competition and clinical trial timelines.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

Revolution Medicines is trending as investors react to a failed acquisition attempt by Merck, which reportedly pulled out of talks due to valuation disagreements, while the community continues to closely track upcoming Phase 3 clinical data for its leading oncology candidate, daraxonrasib.

NXP Semiconductors NV is a holding company which engages in the provision of semiconductor solutions. It operates through the following geographical segments: China, Netherlands, United States, Singapore, Germany, Japan, South Korea, Malaysia, and Other Countries. The company was founded on August 2, 2006, and is headquartered in Eindhoven, the Netherlands.

NXP Semiconductors NV

NXP Semiconductors (NXPI) is trending as institutional investors rotate into automotive and industrial silicon plays following broad-market volatility and robust earnings reactions. The community is actively discussing the company's breakout potential as it positions itself as a critical player in AI-enabled automotive infrastructure and edge computing.

Stellar is an open-source, decentralized network co-founded in 2014 by Jed McCaleb and Joyce Kim to facilitate the fast and low-cost transfer of value across different currencies and assets globally. Managed by the non-profit Stellar Development Foundation, the project serves as a global infrastructure that connects banks, payment systems, and individuals to expand financial access to underserved populations. Its main value proposition lies in providing a bridge between traditional money and digital networks through the use of Anchors, which are trusted entities that hold deposits and issue credits on the ledger.  The network operates using the Stellar Consensus Protocol and a Federated Byzantine Agreement, where nodes choose trusted sets of other nodes to agree on the state of the ledger. This system ensures high throughput and fast finality, where transactions are considered permanent and irreversible within seconds. Key features include a built-in distributed exchange for trading assets without intermediaries and the Soroban platform for developing smart contracts. Users can also utilize the network for tokenizing real-world assets or accessing decentralized finance services like peer-to-peer lending.  Stellar's native token, XLM, is essential for maintaining network integrity by acting as an intermediary to find efficient exchange paths and preventing spam through small transaction fees and minimum account balance requirements. Unlike many other digital assets, the network has no inflation because the community voted to disable the automatic creation of new tokens. While the project received early funding from the payments company Stripe, it is now sustained by a global community of validators and developers rather than traditional venture capital.

Stellar Lumens

Stellar Lumens is trending significantly as investors react to the DTCC's selection of the network to support its massive, trillion-dollar asset tokenization infrastructure. The community is actively debating the project's long-term utility against traditional finance requirements, with many speculating on future price potential as the market reacts to the news of institutional integration.

Hyperliquid Strategies, Inc. is a holding and operating company, which engages in the business of crypto asset management. The firm operates as a digital asset treasury company which focuses on the Hyperliquid ecosystem. The company was founded on July 2, 2025 and is headquartered in New York, NY.

Hyperliquid Strategies Inc.

Hyperliquid Strategies Inc. (PURR) is trending as traders speculate on a potential short squeeze, driven by significant institutional accumulation and its role as a proxy for the rapidly expanding Hyperliquid perpetual futures exchange. The community is actively discussing the stock's massive daily volume and the broader integration of tokenized assets into the U.S. financial system, fueling expectations of a long-term structural rally.

Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments using a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Miami, FL.

Pulse Biosciences Inc

Pulse Biosciences is trending due to heightened investor interest surrounding a rights offering and significant insider accumulation from leadership, signaling confidence in its novel nanosecond pulsed field ablation technology. Community discussion is heavily focused on the company's long-term commercial potential in the cardiac and soft tissue markets, with many participants actively monitoring the stock for a short squeeze setup.

SAP SE engages in the provision of enterprise application software and software-related services. It operates through the following segments: Applications, Technology, and Support; Qualtrics; and Services. The Applications, Technology, and Services segment includes sale of software licenses, support offerings, and cloud subscriptions. The Qualtrics segment sells experience management cloud solutions. The Services segment offers professional services, premium support services, implementation services for software products, and education services on the use of products. The company was founded by Hasso Plattner, Klaus Tschira, Claus Wellenreuther, Dietmar Hopp, and Hans-Werner Hector on April 1, 1972 and is headquartered in Walldorf, Germany.

Sap SE - ADR

SAP AG

SAP is currently trending due to active community debate surrounding the long-term software profit landscape, where investors are weighing its ERP dominance and steady cloud compounding against emerging competitors. While some community members highlight its institutional positioning and recent AI integration efforts, others are debating whether its valuation and cloud growth trajectories justify its market position relative to more aggressive AI-focused rivals.

Virgin Galactic Holdings, Inc. is an aerospace and space travel company, which engages in the provision of consumer space experience using reusable spaceflight systems. The firm is also involved in designing, developing, and manufacturing, ground and flight testing, spaceflight operation, and post-flight maintenance of spaceflight systems. The company was founded on May 5, 2017 and is headquartered in Tustin, CA.

Virgin Galactic Holdings Inc - Ordinary Shares - Class A

Virgin Galactic Holdings Inc

Virgin Galactic is experiencing a massive surge in trading volume and retail attention as investors position it as a proxy play ahead of the highly anticipated SpaceX IPO. The community is sharply divided, with bulls betting on a potential gamma squeeze driven by high short interest and speculative hype, while bears warn of the company's weak fundamentals and the risk of a sharp correction.

BNB is the native utility token of the BNB Chain ecosystem, acting as a multi-chain asset that powers decentralized applications and facilitates value exchange across its network. It serves as the primary asset for paying transaction gas and smart contract deployment fees while providing users with tiered fee discounts on the Binance exchange. The project’s main value proposition lies in its unified multi-chain architecture, which integrates a smart contract platform, a Layer 2 scaling solution, and a decentralized data storage network into a cohesive settlement and data availability layer.  The network operates on a Proof of Staked Authority consensus mechanism, utilizing a group of 21 active validators known as the Cabinet to verify transactions and produce blocks every 3 seconds. Validators are elected daily based on the amount of BNB staked or delegated to them, and the system employs fast finality and slashing penalties to maintain security and integrity. To manage its long-term economy, the project uses a programmatic dual-burn strategy that permanently removes tokens through real-time fee destruction and quarterly buybacks.  Launched in 2017 by the Binance platform, the project initially distributed 50% of its 200 million token supply to the public, while the founding team received 40% and angel investors were allocated 10%. Though it began as a token on the Ethereum network, it eventually migrated to its own autonomous architecture that remains fully compatible with the Ethereum Virtual Machine. Today, the token's utility includes paying for network gas, participating in staking rewards, and enabling decentralized governance through which holders can vote on technical upgrades and economic changes.

Binance

Binance's BNB is experiencing significant community attention as traders analyze its price consolidation and long-term utility alongside broader market volatility. Investors are actively discussing the token's technical patterns, institutional developments, and its role as a major asset in decentralized finance.

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is facing significant community debate as retail investors express frustration over long-term price stagnation while weighing potential breakout catalysts against market skepticism. Discussions remain polarized between holders anticipating a reversal and critics comparing the asset's performance to broader market trends.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BML Capital Management LLC Sells 858,613 Shares of Connect Biopharma Holdings Limited Sponsored ADR $CNTB

BML Capital Management LLC lowered its holdings in shares of Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB - Free Report) by 67.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owne...

Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Given Average Rating of "Moderate Buy" by Analysts

Shares of Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB - Get Free Report) have been given a consensus rating of "Moderate Buy" by the five research firms that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, three have assig...

Northland Securities Weighs in on CNTB Q1 Earnings

Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB - Free Report) - Equities research analysts at Northland Securities issued their Q1 2026 earnings per share (EPS) estimates for Connect...

Q1 Earnings Estimate for CNTB Issued By HC Wainwright

Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB - Free Report) - Stock analysts at HC Wainwright issued their Q1 2026 earnings estimates for shares of Connect Biopharma in a research note issued on Wednesday, April 8th. HC Wainwright analyst B. Folkes expects that the company will post...

Shares of Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the five ratings firms that are currently...

Connect Biopharma (NASDAQ:CNTB) Director Buys $4,002,000.00 in Stock

Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB - Get Free Report) Director James Huang acquired 1,160,000 shares of Connect Biopharma stock in a transaction that occurred on Tuesday...

Connect Biopharma (NASDAQ:CNTB) Director James Huang Acquires 1,160,000 Shares

Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB - Get Free Report) Director James Huang bought 1,160,000 shares of the stock in a transaction on Tuesday, March 31st. The stock was purchased at an average cost of $3.45 per share, with a total value of $4,002,000.00. Following the...

Connect Biopharma (NASDAQ:CNTB) Posts Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Connect Biopharma (NASDAQ:CNTB - Get Free Report) posted its earnings results on Tuesday. The company reported ($0.27) earnings per share for the quarter, topping analysts' consensus estimates of...

Connect Biopharma (NASDAQ:CNTB) Receives "Buy" Rating from BTIG Research

BTIG Research restated a "buy" rating and issued a $10.00 price target on shares of Connect Biopharma in a research report on Tuesday...

Connect Biopharma touts rapid IV rademikibart FEV1 gains; Phase 3 atopic dermatitis data impresses

Connect Biopharma (NASDAQ:CNTB) shared new clinical and preclinical updates on rademikibart, its IL-4 receptor alpha monoclonal antibody, highlighting preliminary top-line results from an intravenous...

Connect Biopharma Holdings Ltd. operates as clinical-stage biopharmaceutical company. It focuses on advancing rademikibart, an anti-interleukin-4-receptor alpha antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease. The company was founded by Zheng Wei and Wu Bin Pan on November 23, 2015 and is headquartered in San Diego, CA.

CNTB
Connect Biopharma Holdings Ltd - ADR

Feed

News

Sentiment

Fundamentals

Info

Compact View

Latest CNTB News

CNTBConnect Biopharma Holdings Ltd - ADR